BRPI0508514A - aril piperidinas ou piperazinas substituìdas por heterociclos de 5-membros inibidoras de mtp - Google Patents
aril piperidinas ou piperazinas substituìdas por heterociclos de 5-membros inibidoras de mtpInfo
- Publication number
- BRPI0508514A BRPI0508514A BRPI0508514-4A BRPI0508514A BRPI0508514A BR PI0508514 A BRPI0508514 A BR PI0508514A BR PI0508514 A BRPI0508514 A BR PI0508514A BR PI0508514 A BRPI0508514 A BR PI0508514A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- diabetes
- membered heterocycles
- mtp inhibitor
- mtp
- Prior art date
Links
- -1 aryl piperidines Chemical group 0.000 title abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000004885 piperazines Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 101150102415 Apob gene Proteins 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
ARIL PIPERIDINAS OU PIPERAZINAS SUBSTITUìDAS POR HETEROCICLOS DE 5-MEMBROS INIBIDORAS DE MTP. A presente invenção diz respeito a novos compostos de aril piperidina ou piperazina substituídos por certos heterociclos de cinco membros tendo atividade de inibição de MTP/secreção de apoB e concomitante atividade de redução de lipídeos. A invenção também refere-se a métodos para preparar tais compostos, composições farmacêuticas compreendendo os referidos compostos, bem como o uso dos referidos compostos como uma medicina para o tratamento de hiperlipidemia, obesidade e diabetes tipo II (Fórmula(I)) A invenção também refere-se a métodos para preparar tais compostos, composições farmacêuticas compreendendo os referidos compostos, bem como o uso dos referidos compostos como uma medicina para o tratamento de aterosclerose, pancreatite, obesidade, hipertrigliceridemia, hipercolesterolemia, hiperlipidemia, diabetes e diabetes do tipo II.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04075771 | 2004-03-10 | ||
| US55633604P | 2004-03-25 | 2004-03-25 | |
| PCT/EP2005/051010 WO2005085226A1 (en) | 2004-03-10 | 2005-03-07 | Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0508514A true BRPI0508514A (pt) | 2007-08-14 |
Family
ID=34928108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0508514-4A BRPI0508514A (pt) | 2004-03-10 | 2005-03-07 | aril piperidinas ou piperazinas substituìdas por heterociclos de 5-membros inibidoras de mtp |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7504400B2 (pt) |
| EP (1) | EP1751131B1 (pt) |
| JP (1) | JP4846709B2 (pt) |
| KR (1) | KR101171211B1 (pt) |
| CN (1) | CN1930143B (pt) |
| AR (1) | AR048316A1 (pt) |
| AT (1) | ATE414698T1 (pt) |
| AU (1) | AU2005219580B2 (pt) |
| BR (1) | BRPI0508514A (pt) |
| CA (1) | CA2558506C (pt) |
| DK (1) | DK1751131T3 (pt) |
| EA (1) | EA009455B1 (pt) |
| ES (1) | ES2317206T3 (pt) |
| IL (1) | IL177939A (pt) |
| JO (1) | JO2537B1 (pt) |
| MX (1) | MXPA06010253A (pt) |
| MY (1) | MY142521A (pt) |
| NZ (1) | NZ548817A (pt) |
| PA (1) | PA8625401A1 (pt) |
| PL (1) | PL1751131T3 (pt) |
| PT (1) | PT1751131E (pt) |
| SI (1) | SI1751131T1 (pt) |
| TW (1) | TWI353984B (pt) |
| UA (1) | UA85215C2 (pt) |
| WO (1) | WO2005085226A1 (pt) |
| ZA (1) | ZA200607542B (pt) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ566877A (en) | 2005-09-29 | 2010-05-28 | Sanofi Aventis | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| US8183239B2 (en) | 2005-10-31 | 2012-05-22 | Janssen Pharmaceutica Nv | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| ATE547394T1 (de) * | 2006-12-01 | 2012-03-15 | Bristol Myers Squibb Co | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen |
| DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| WO2009079593A1 (en) * | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica N.V. | Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor |
| US20090197947A1 (en) * | 2008-02-01 | 2009-08-06 | The Research Foundation Of State University Of New York | Medicaments and methods for lowering plasma lipid levels and screening drugs |
| CN102083839B (zh) | 2008-02-06 | 2014-03-26 | 阿斯利康(瑞典)有限公司 | 化合物 |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| AU2011254654B2 (en) * | 2010-05-19 | 2016-01-07 | Sandoz Ag | Process for the preparation of chiral triazolones |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN104334547B (zh) | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | 作为kv3抑制剂的三唑类 |
| MX364895B (es) | 2013-03-13 | 2019-05-10 | Forma Therapeutics Inc | Nuevos compuestos y composiciones para la inhibicion de fasn. |
| CN105143210A (zh) * | 2013-04-25 | 2015-12-09 | 柳韩洋行 | 新的三唑酮衍生物或其盐以及含有其的药物组合物 |
| EP3010893B1 (de) | 2013-06-20 | 2019-10-02 | Bayer CropScience Aktiengesellschaft | Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide |
| BR112015031155A2 (pt) | 2013-06-20 | 2017-07-25 | Bayer Cropscience Ag | derivados de sulfureto de arila e derivados de aril sulfóxido como acaricidas e inseticidas |
| EP3028703B1 (en) | 2013-07-29 | 2019-12-04 | Kyowa Kirin Co., Ltd. | Piperidine derivatives as wnt signaling inhibitor |
| US10301318B2 (en) * | 2014-06-25 | 2019-05-28 | The General Hospital Corporation | Neuroactive compounds and methods of using the same |
| GB201601301D0 (en) * | 2016-01-25 | 2016-03-09 | Takeda Pharmaceutical | Novel compounds |
| WO2017205709A1 (en) * | 2016-05-27 | 2017-11-30 | Bristol-Myers Squibb Company | Triazolones and tetrazolones as inhibitors of rock |
| AU2017295745A1 (en) | 2016-07-12 | 2019-01-31 | Bayer Cropscience Aktiengesellschaft | Bicyclic compounds as pest control agents |
| CN110198942B (zh) | 2017-01-24 | 2022-04-15 | 住友化学株式会社 | 稠合杂环化合物及含有其的组合物 |
| BR112021002207A2 (pt) | 2018-08-10 | 2021-05-04 | Diapin Therapeutics, Llc | tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
| WO2022187206A1 (en) * | 2021-03-01 | 2022-09-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual-target mu opioid and dopamine d3 receptors ligands; preparation and use thereof |
| WO2023225041A1 (en) * | 2022-05-19 | 2023-11-23 | Merck Sharp & Dohme Llc | Ripk1 inhibitors and methods of use |
| GB202216960D0 (en) * | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9826412D0 (en) * | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
| GB0013346D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
-
2005
- 2005-03-07 WO PCT/EP2005/051010 patent/WO2005085226A1/en not_active Ceased
- 2005-03-07 BR BRPI0508514-4A patent/BRPI0508514A/pt not_active Application Discontinuation
- 2005-03-07 DK DK05716940T patent/DK1751131T3/da active
- 2005-03-07 CA CA2558506A patent/CA2558506C/en not_active Expired - Fee Related
- 2005-03-07 KR KR1020067016095A patent/KR101171211B1/ko not_active Expired - Fee Related
- 2005-03-07 PT PT05716940T patent/PT1751131E/pt unknown
- 2005-03-07 SI SI200530555T patent/SI1751131T1/sl unknown
- 2005-03-07 JP JP2007502335A patent/JP4846709B2/ja not_active Expired - Fee Related
- 2005-03-07 JO JO200526A patent/JO2537B1/en active
- 2005-03-07 AU AU2005219580A patent/AU2005219580B2/en not_active Ceased
- 2005-03-07 EP EP05716940A patent/EP1751131B1/en not_active Expired - Lifetime
- 2005-03-07 CN CN2005800074663A patent/CN1930143B/zh not_active Expired - Fee Related
- 2005-03-07 ES ES05716940T patent/ES2317206T3/es not_active Expired - Lifetime
- 2005-03-07 NZ NZ548817A patent/NZ548817A/en not_active IP Right Cessation
- 2005-03-07 EA EA200601660A patent/EA009455B1/ru not_active IP Right Cessation
- 2005-03-07 MX MXPA06010253A patent/MXPA06010253A/es active IP Right Grant
- 2005-03-07 US US10/589,515 patent/US7504400B2/en not_active Expired - Lifetime
- 2005-03-07 PL PL05716940T patent/PL1751131T3/pl unknown
- 2005-03-07 AT AT05716940T patent/ATE414698T1/de active
- 2005-03-08 PA PA20058625401A patent/PA8625401A1/es unknown
- 2005-03-09 TW TW094107062A patent/TWI353984B/zh not_active IP Right Cessation
- 2005-03-09 AR ARP050100904A patent/AR048316A1/es not_active Application Discontinuation
- 2005-03-09 MY MYPI20050983A patent/MY142521A/en unknown
- 2005-07-03 UA UAA200608684A patent/UA85215C2/uk unknown
-
2006
- 2006-09-07 IL IL177939A patent/IL177939A/en not_active IP Right Cessation
- 2006-09-08 ZA ZA200607542A patent/ZA200607542B/en unknown
-
2008
- 2008-12-22 US US12/341,567 patent/US7816360B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2537B1 (en) | Aryl-pyridine or pyrezinate compounds replaced with heterogeneous pentagonal rings used as inhibitors of MTB proteins | |
| NO20092005L (no) | MTP-Inhiberende piperidin- eller piperazinsubstituerte tetrahydro-naftalen-1-karboksylsyreforbindelser | |
| BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
| CY1112646T1 (el) | Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1α | |
| CY1106857T1 (el) | Βενζαμιδια 4-(αμινομεθυλ)-πιπεριδινης ως 5ht4-ανταγωνιστες | |
| BRPI0619823A8 (pt) | compostos que são inibidores de erk | |
| DE60315336D1 (de) | Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv) | |
| NO20071137L (no) | Nye piperidinderivater for behandling av depresjon | |
| NO20063928L (no) | Substituerte kinolinforbindelser | |
| DOP2010000137A (es) | Derivados de 1,2,3-triazol como inhibidores de estearoil-coenzima a desaturasa | |
| AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
| AR072242A1 (es) | Derivados de imidazopiridina, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neuromusculares. | |
| ATE348610T1 (de) | 1-(2h-pyrazol-3-yl)-3-ä4-(1-(benzoyl)-piperidin 4-ylmethyl)-phenylü-harnstoffderivate und verwandte verbindungen als inhibitoren der p38 kinase und/oder des tnf zur behandlung von entzündungen | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| BR0313377A (pt) | Bifenilcarnboxamidas substituìdas por n-aril piperidina como inibidores de secreção de apolipoproteìna b | |
| BRPI0513891B8 (pt) | derivados de propenil piperazina substituídos, seu uso como novos inibidores de histona deacetilase, composição farmacêutica, combinação e processo de preparação destes | |
| BRPI0407968A (pt) | derivados de oxamida úteis como inibidores de raf-quinase | |
| EA200601120A1 (ru) | N-арилпиперидинзамещённые бифинилкарбоксамиды в качестве ингибиторов аполипопротеина в | |
| ATE412636T1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
| DE602007006833D1 (de) | Mtp-inhibierende tetrahydronaphthalin-1-carbonsäurederivate | |
| CY1115153T1 (el) | Μεθοδοι για την αγωγη δερματολογικων διαταραχων | |
| BRPI0408148A (pt) | derivados de ácido benzoilureidopiridil-piperidina e -pirrolidina-carboxìlico, processos para a preparação e uso dos mesmos | |
| CY1108764T1 (el) | Μτρ ανασταλτικες αρυλ πιπεριδινες ή πιπεραζινες υποκατεστημενες με 5-μελεις ετεροκυκλους | |
| ATE308513T1 (de) | Naphthamid-neurokinin antagonisten zur verwendung als medikamente | |
| RU2012128865A (ru) | Производные 4-(азациклоалкил)-бензол-1,3-диола в качестве ингибиторов тирозиназы, их синтез и применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |